Biosimilar Uptake Gains Momentum In The US
Payer And Provider Strategies To Encourage Uptake Are Gaining Traction
Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress.
You may also be interested in...
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.